Schering: Competitor Switch Of Rx Antihistamine, Nasal Steroid Anticipated
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough expects the over-the-counter switch or generic availability of a competing Rx antihistamine or nasal steroid to impact its 2004 fiscal year earnings